secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-021169
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Pharma Q4 net income $45.8M; 2023 revenue $726.4M (+40%); FY2024 DAYBUE guide $370-420M
--------------------------------------------------------------------------------

- Q4 2023 net income $45.8M ($0.28 EPS) vs net loss $41.7M ($0.26 loss) in Q4 2022.
- Full year 2023 net loss $61.3M ($0.37 loss) vs net loss $216.0M ($1.34 loss) in 2022.
- 2023 total net product sales $726.4M (+40% YoY); DAYBUE $177.2M, NUPLAZID $549.2M (+6%).
- FY2024 guidance: DAYBUE net sales $370-420M; NUPLAZID $560-590M; R&D $305-325M; SG&A $455-480M.
- Phase 3 ADVANCE-2 (pimavanserin for negative schizophrenia) top-line results due by end of Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017024021169/0000950170-24-021169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017024021169/acad-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer